Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0KA9L
|
|||
| Former ID |
DNCL002744
|
|||
| Drug Name |
AME-133v
|
|||
| Synonyms |
Ocaratuzumab
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 2 | [1], [2], [3] | |
| Company |
MENTRIK Biotech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte surface antigen Leu-16 (CD20) | Target Info | . | [4] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00354926) Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma. U.S. National Institutes of Health. | |||
| REF 2 | J Clin Oncol 30, 2012 (suppl, abstr 8081). | |||
| REF 3 | Clinical pipeline report, company report or official report of MENTRIK Biotech. | |||
| REF 4 | Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcgammaRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res. 2012 Mar 1;18(5):1395-403. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.